Related Experiment Video
Updated: Jul 20, 2026
06:41
A New Technique for Quantitative Analysis of Hair Loss in Mice Using Grayscale Analysis
Published on: March 9, 2015
Protection against chemotherapy-induced alopecia
Jie Wang1, Ze Lu, Jessie L-S Au
1College of Pharmacy, The Ohio State University, Columbus, Ohio, USA.
Pharmaceutical Research
|September 15, 2006
Summary
Advances in preventing chemotherapy-induced alopecia (CIA) are reviewed, focusing on hair follicle biology, CIA characteristics, animal models, and protective strategies. Calcitriol and cyclosporine A show broad-spectrum potential against CIA.
Area of Science:
- Oncology
- Dermatology
- Pharmacology
Background:
- Chemotherapy-induced alopecia (CIA) is a significant side effect impacting patient quality of life.
- The hair follicle is an unintended target of cancer chemotherapy.
- Addressing CIA is an unmet need, particularly for female and pediatric cancer patients.
Purpose of the Study:
- To provide a comprehensive overview of recent advancements in the protection against chemotherapy-induced alopecia (CIA).
Main Methods:
- Review of hair follicle biology and CIA characteristics.
- Analysis of current animal models for CIA.
- Evaluation of experimental approaches and pharmacological agents for CIA protection.
Main Results:
- Significant progress in understanding CIA pathobiology over the last decade.
- Various agents evaluated include antibodies, growth factors, antioxidants, and apoptosis inhibitors.
- Calcitriol and cyclosporine A demonstrate broader spectrum activity against multiple chemotherapeutic agents in animal models.
Conclusions:
- Multiple agent classes show efficacy in animal CIA models, but many are agent-specific.
- Calcitriol and cyclosporine A offer broader protection against various chemotherapeutic agents.
- Human trials with AS101 and Minoxidil showed reduced CIA severity/duration, but not complete prevention.
Related Concept Videos
01:29Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates these...
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
01:21Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...